OKYO Pharma Secures US Patent for Dry Eye Treatment
Ticker: OKYO · Form: 6-K · Filed: Aug 27, 2024 · CIK: 1849296
Sentiment: bullish
Topics: patent, pharmaceutical, dry-eye-disease
TL;DR
OKYO Pharma just got a US patent for its dry eye drug OK-101. Big win for IP.
AI Summary
On August 27, 2024, OKYO Pharma Ltd announced the grant of U.S. Patent No. 12,053,501, issued on August 6th, for "Methods for Treating Symptoms of Dry Eye Disease." This patent covers the use of OK-101 in treating dry eye disease symptoms.
Why It Matters
This patent grant is a significant step for OKYO Pharma, potentially strengthening its intellectual property portfolio and market position for its dry eye disease treatment.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a granted patent, which is generally positive news with low immediate risk.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- U.S. Patent No. 12,053,501 (patent) — Granted patent for dry eye treatment
- OK-101 (drug) — Product covered by the patent
- August 27, 2024 (date) — Date of announcement
- August 6th (date) — Date patent was issued
FAQ
What is the title of the granted U.S. Patent No. 12,053,501?
The title of the patent is "Methods for Treating Symptoms of Dry Eye Disease."
When was U.S. Patent No. 12,053,501 officially issued?
U.S. Patent No. 12,053,501 was issued on August 6th.
What is the primary indication covered by the new patent for OKYO Pharma?
The patent covers the use of OK-101 for treating symptoms of Dry Eye Disease.
What form was filed with the SEC to announce this patent grant?
OKYO Pharma LTD filed a Form 6-K to announce the patent grant.
What is the company's principal executive office address?
The company's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 370 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-08-27 07:00:04
Filing Documents
- form6-k.htm (6-K) — 24KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001493152-24-033936.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: August 27, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated August 27, 2024 4